Choosing the optimal nonstatin lipid-lowering therapies for statin-intolerant patients: A systematic review and...

Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.

This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.

We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents. The primary outcome was low-density lipoprotein cholesterol (LDL-C). A random-effects model estimated comparative effects using mean differences (MDs) for LDL-C reduction and relative risks (RRs) for safety outcomes, specifically trial withdrawal due to adverse events. Results were reported with 95% CIs, and therapies ranked using the surface under the cumulative ranking curve (SUCRA). Evidence certainty was assessed with the Confidence in Network Meta-Analysis (CINeMA) platform.

Of 1533 articles, 6 studies (1326 patients) met inclusion criteria. Evolocumab combined with ezetimibe achieved the greatest LDL-C reduction (MD: 48.98%; 95% CI: 59.19, -38.77) vs ezetimibe alone, with moderate evidence certainty. Evolocumab, alirocumab, and the combination of bempedoic acid and ezetimibe, also showed significant reductions in LDL-C compared to ezetimibe monotherapy, though the magnitude of their effects was smaller than that of the evolocumab and ezetimibe combination. The SUCRA of evolocumab and ezetimibe (99.7%) aligns with its highest comparative efficacy. No significant differences in safety outcomes were observed across treatments.

Evolocumab combined with ezetimibe is the most effective regimen for LDL-C reduction, with a safety profile comparable to other treatments, making it a viable alternative for patients with statin intolerance.